At the gene level, the concordance rate was variable among the known BC driver-genes—100% for FGFR1/ZNF703 and ERRB2, 86% for CCND1 (indicating possible differences in the sensitivity to CDK-inhibitors between PBC and the paired BM), and 65% for MYC. Here, ZNF703 is linked to breast cancer.